:
In this second part of a review of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial
(IMPROVE-IT), we discuss the findings in relation to patients with stroke, the ACS phenotype, history of coronary artery
bypass graft surgery, heart failure, concurrent polyvascular atherosclerotic cardiovascular disease (ASCVD) and diabetes
mellitus, and different levels of expression of selected cardiovascular biomarkers. The combination therapy was proven safe,
and drug discontinuation rates were not increased by adding ezetimibe. Since both statins and ezetimibe are now almost
globally generically available, we can conclude that for secondary prevention of ASCVD, adding ezetimibe to high-intensity
statin therapy further reduces low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk cost-effectively.